BriaCell Therapeutics Corp. (BCTX) stock
BCTXNasdaqPharmaceutical PreparationsFiscal year ends July 31Also trades as BCTXL, BCTXZ
Số liệu tài chính tới Q4 năm tài chính 2026, quý kết thúc ngày Jul 31, 2026Last filing: 10-K on Oct 28, 2026Score 4/30
$3.51+0.21 (+6.36%)
Close on Nov 17, 2026Market cap $30.65MP/E –Yield –
BriaCell Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
BriaCell Therapeutics's R&D Expenses for the twelve months ending Jul 31, 2026 was $29.24M, up 37.4% year over year. For fiscal 2026 it was $29.24M, up 37.4% from the year before. The highest annual figure on record is $29.24M in fiscal 2026.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jul 31, 2026 | $29.24M | +37.4% |
| FY2025 | Jul 31, 2025 | $21.27M | -21.7% |
| FY2024 | Jul 31, 2024 | $27.18M | +77.2% |
| FY2023 | Jul 31, 2023 | $15.34M | +91.2% |
| FY2022 | Jul 31, 2022 | $8.02M | +296.9% |
| FY2021 | Jul 31, 2021 | $2.02M | -16.7% |
| FY2020 | Jul 31, 2020 | $2.43M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ2 2026 | Jul 31, 2026 | $10.53M | +48.1% |
| Q3 FY2026CQ1 2026 | Apr 30, 2026 | $5.97M | +24.0% |
| Q2 FY2026CQ4 2025 | Jan 31, 2026 | $6.05M | +6.5% |
| Q1 FY2026CQ3 2025 | Oct 31, 2025 | $6.68M | +82.3% |
| Q4 FY2025CQ2 2025 | Jul 31, 2025 | $7.11M | +61.4% |
| Q3 FY2025CQ1 2025 | Apr 30, 2025 | $4.81M | -37.2% |
| Q2 FY2025CQ4 2024 | Jan 31, 2025 | $5.68M | -31.2% |
| Q1 FY2025CQ3 2024 | Oct 31, 2024 | $3.67M | -46.5% |
| Q4 FY2024CQ2 2024 | Jul 31, 2024 | $4.41M | -14.7% |
| Q3 FY2024CQ1 2024 | Apr 30, 2024 | $7.66M | +98.4% |
| Q2 FY2024CQ4 2023 | Jan 31, 2024 | $8.26M | +170.4% |
| Q1 FY2024CQ3 2023 | Oct 31, 2023 | $6.86M | +110.7% |
| Q4 FY2023CQ2 2023 | Jul 31, 2023 | $5.17M | +63.1% |
| Q3 FY2023CQ1 2023 | Apr 30, 2023 | $3.86M | +70.2% |
| Q2 FY2023CQ4 2022 | Jan 31, 2023 | $3.05M | +78.7% |
| Q1 FY2023CQ3 2022 | Oct 31, 2022 | $3.26M | +271.8% |
| Q4 FY2022CQ2 2022 | Jul 31, 2022 | $3.17M | +445.6% |
| Q3 FY2022CQ1 2022 | Apr 30, 2022 | $2.27M | +101.6% |
| Q2 FY2022CQ4 2021 | Jan 31, 2022 | $1.71M | +931.6% |
| Q1 FY2022CQ3 2021 | Oct 31, 2021 | $875.64K | – |
| Q4 FY2021CQ2 2021 | Jul 31, 2021 | $580.82K | – |
| Q3 FY2021CQ1 2021 | Apr 30, 2021 | $1.13M | – |
| Q2 FY2021CQ4 2020 | Jan 31, 2021 | $165.59K | – |
See a number that looks wrong?